Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

Immunoglobulin light chain amyloidosis remains incurable despite recent therapeutic advances, and is particularly difficult to treat in patients with amyloid cardiomyopathy. Based on evidence of activity in multiple myeloma, we designed a pilot study of an oral regimen of lenalidomide in combination...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Dinner, Shira, Witteles, Wesley, Afghahi, Anosheh, Witteles, Ronald, Arai, Sally, Lafayette, Richard, Schrier, Stanley L., Liedtke, Michaela
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2013
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3789465/
https://ncbi.nlm.nih.gov/pubmed/23716538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.084574
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים